Streetbeat News

Stock Prices

SCPX

Scorpius Holdings shares are trading lower following the pricing of a 60 million unit offering at $0.10 per unit.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 7:25 pm

FFIE

Faraday Future Intelligent Electric shares are trading higher, possibly amid strength in high-short interest stocks.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 7:24 pm

DIA

IWM

QQQ

SPY

Major indexes have rebounded from earlier losses triggered by April's inflation data surpassing expectations.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 7:19 pm

BA

LMT

The Lockheed-Boeing alliance is facing penalties from the U.S. Air Force due to a delay in launch schedules, with specific details on the withheld fees not disclosed. The Air Force has cited a 'schedule slip' as the reason for the penalties.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 7:04 pm

FILUSD

Cryptocurrency Filecoin (FIL) experienced a 3.46% price decrease over the past 24 hours, marking a continuation of its -9.0% decline over the past week. The trading volume for FIL has decreased by 17.0%, while its circulating supply has increased by 0.53%. Currently, FIL's market cap ranks it 39th at $2.97 billion.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:03 pm

IMXUSD

Immutable's cryptocurrency, IMX, has seen a 7.64% decrease in price over the last 24 hours, continuing a negative trend with a 7.0% loss over the past week. Despite this, trading volume for IMX has increased by 16.0%, and its circulating supply has slightly risen. Currently, IMX's market cap ranks it 37th at $3.00 billion.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:02 pm

CAPR

Capricor Therapeutics (NASDAQ:CAPR) has seen diverse analyst ratings over the last three months, with a recent shift towards more bullish outlooks. The average 12-month price target has increased to $30.6, up from $24.00, indicating a positive sentiment shift. The company, focusing on biological therapies for diseases like Duchenne muscular dystrophy, has shown impressive financial performance with significant revenue growth and strong profitability metrics.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:01 pm

FOLD

Amicus Therapeutics (NASDAQ:FOLD) has received mixed reviews from 6 financial analysts over the past quarter, with ratings ranging from bullish to bearish. The average 12-month price target is $17.5, with a high of $22.00 and a low of $13.00, marking a 6.67% decline from the previous average. Analysts have adjusted their ratings and price targets, reflecting their latest views on the company's performance and market conditions. Amicus Therapeutics is a biotech company focused on rare metabolic diseases, showing strong market position, revenue growth, and financial performance despite some challenges in ROE and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:00 pm

HUM

Humana (NYSE:HUM) has significantly outperformed the market with an average annual return of 16.65% over the past 20 years, turning a $100 investment into $2,183.35 today. The company's market capitalization currently stands at $40.39 billion.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:00 pm

TXN

Texas Instruments (NASDAQ:TXN) has delivered an average annual return of 16.88% over the past 15 years, outperforming the market by 4.48% annually. A $100 investment in TXN 15 years ago would be worth $1,056.75 today. The company's current market capitalization stands at $173.96 billion.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:00 pm